News | March 15, 2026
China’s NMPA approves Zydus-licensed anaemia drug Desidustat
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
This license is a key regulatory milestone in advancing Hester's prevention-led poultry healthcare portfolio
Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
The antibody was designed and developed at Abzena’s Cambridge, UK,
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
The sudden subsequent decision to suspend IXCHIQ is based on updated VAERS data
Subscribe To Our Newsletter & Stay Updated
